Who are Sevoflurane and Remifentanil's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sevoflurane-and-remifentanil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Sevoflurane and Remifentanil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sevoflurane and Remifentanil (Sevoflurane and Remifentanil) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: General anesthetic (sevoflurane) and synthetic opioid analgesic (remifentanil). Area: Anesthesiology.

marketed General anesthetic (sevoflurane) and synthetic opioid analgesic (remifentanil) GABA receptors (sevoflurane); mu-opioid receptor (remifentanil) Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Sevoflurane and Remifentanil (Sevoflurane and Remifentanil) — University General Hospital of Patras. Sevoflurane is a volatile anesthetic that depresses the central nervous system, while remifentanil is a potent synthetic opioid that provides analgesia and enhances anesthesia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sevoflurane and Remifentanil TARGET	Sevoflurane and Remifentanil	University General Hospital of Patras	marketed	General anesthetic (sevoflurane) and synthetic opioid analgesic (remifentanil)	GABA receptors (sevoflurane); mu-opioid receptor (remifentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (General anesthetic (sevoflurane) and synthetic opioid analgesic (remifentanil) class)

University General Hospital of Patras · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sevoflurane and Remifentanil — Competitive Intelligence Brief. https://druglandscape.com/ci/sevoflurane-and-remifentanil. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab